Thrombocytopenia valganciclovir

The clinical toxicity of valganciclovir, which is metabolized to ganciclovir, includes granulocytopenia, anemia, and thrombocytopenia. In animal studies, ganciclovir was carcinogenic, teratogenic, and caused aspermatogenesis. 

Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, and aplastic anemia have been observed in patients treated with valganciclovir tablets (and ganciclovir) (see Precautions and Adverse Reactions). 

In an open pharmacokinetic assessment of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients, most of the treatment-related adverse events were gastrointestinal and mild or moderate in intensity [14 ]. Of 26 renal transplant patients, treatment-related adverse events occurred in 4 taking oral valganciclovir nausea in 1, vomiting in 1, and headache in 2) and in 1 on intravenous ganciclovir thrombocytopenia). Of 20 liver... 

---